LRI Investments’s Amneal Pharmaceuticals AMRX Stock Holding History

LRI Investments’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$225	Buy	+13	New	+$178	﹤0.01%	1717

Other funds holding AMRX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

PCM

Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PFC

Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

CIP

Convergence Investment Partners Palm Beach Gardens, Florida $1.06B AUM 87.75% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

LRI Investments's AMRX Position: Q2 2026 in Review

LRI Investments opened a new position in Amneal Pharmaceuticals (AMRX) in Q2 2026: 13 shares worth $225. The stake represents ﹤0.01% of the portfolio and ranks #1717 among its holdings.

76 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

LRI Investments held 13 shares of Amneal Pharmaceuticals worth $225 as of Q2 2026.
Amneal Pharmaceuticals was a new LRI Investments position in Q2 2026.
Amneal Pharmaceuticals made up ﹤0.01% of LRI Investments's portfolio in Q2 2026, its #1717 holding.
76 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on LRI Investments's 13F filing for Q2 2026, filed 14 Jul 2026.